Approved “Water Pill” Bumetanide May Reduce Alzheimer’s Risk
Analyzing large databases of human data, scientists identified a “water pill” called bumetanide, which reduced the risk of developing Alzheimer’s for people with a…
Analyzing large databases of human data, scientists identified a “water pill” called bumetanide, which reduced the risk of developing Alzheimer’s for people with a…
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. Image: Robert Reid and his wife Kimberly….
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
In the future, implantable devices that interface with the brain could help people with severe neurodegenerative movement disorders communicate again through a computer or…
In our LiveTalk series, Being Patient spoke with Marc Archambault about his early symptoms of Alzheimer’s, the ways in which he has adapted his career…
Researchers share insights on the infectious theory of Alzheimer’s—the idea viruses and bacteria may cause Alzheimer’s. Clinical trials are underway to test this theory….
Alzheimer’s is a complex disease, and studies that follow participants over extended periods of time can gather troves of data on the progression of…
A recent cell study shows that experimental Parkinson’s and Alzheimer’s antibodies may trigger harmful brain inflammation—which could explain clinical trials’ dismal failure rates. In…
Scientists in the field of Alzheimer’s have struggled to carry promising findings in mice studies into human trials, but primate researchers believe that animals…
With a strong family history of Alzheimer’s, Dewayne Nash had expected that he would start experiencing symptoms of the disease by the time he…
Scientists still don’t know why some people develop Alzheimer’s and others don’t. But while we may not fully understand the causes of Alzheimer’s, researchers…
Nicotine, a natural product of various plants including the tobacco plant, is notorious for its addictive properties in tobacco products like cigarettes. But the…
Lack of diversity in clinical trials for Alzheimer’s and other diseases is hurting research, experts say. New data offers some solutions. New research presented…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
UPDATE: 3 March 2024, 8:40 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…